EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial

Perioperative Chemotherapie mit Docetaxel plus Oxaliplatin und S-1 (DOS) versus Oxaliplatin plus S-1 (SOX) bei lokal fortgeschrittenem Adenokarzinom des Magens oder des gastroösophagealen Übergangs (MATCH): offene randomisierte Phase-2-Studie

Zhichao Jiang, Yibin Xie, Wen Zhang, Chunxia Du, Yuxin Zhong, Yuelu Zhu, Liming Jiang, Lizhou Dou, Kang Shao, Yongkun Sun, Qi Xue, Yantao Tian und 3 weitere

Gastric Cancer · 2024-05 · 27 (3) · 571-579

DOI: 10.1007/s10120-024-01471-z ↗

Auf einen Blick

DOS erhöhte in dieser Phase-2-Studie die major pathologische Ansprechrate gegenüber SOX. Auch R0-Resektion und 3-Jahres-PFS waren numerisch besser, die Verträglichkeit war ähnlich.

Fragestellung

Verbessert perioperative DOS im Vergleich zu SOX die Wirksamkeit bei lokal fortgeschrittenem Magen- oder GEJ-Adenokarzinom?

Methode

Offene randomisierte Phase-2-Studie; Patient:innen mit cT3–4 N any M0 G/GEJ-Adenokarzinom erhielten 4 Zyklen präoperativ DOS oder SOX, danach D2-Gastrektomie und 4 Zyklen postoperativ. Primärer Endpunkt: MPR.

Ergebnisse

DOS führte zu höherer MPR (25,4 % vs. 11,8 %; P = 0,04). R0-Resektion: 78,9 % vs. 61,8 % (P = 0,02). 3-Jahres-PFS: 52,3 % vs. 35 % (HR 0,667, 95 %-KI 0,432–1,029; Log rank P = 0,07). 3-Jahres-OS: 57,5 % vs. 49,2 % (HR 0,685, 95 %-KI 0,429–1,095; Log rank P = 0,11).

Schlussfolgerung der Autor:innen

Perioperatives DOS verbesserte die MPR signifikant und zeigte einen Trend zu längerem PFS gegenüber SOX; es könnte als bevorzugte Option erwogen werden und verdient weitere Untersuchung.

Kernaussagen

  • MPR: 25,4 % mit DOS vs. 11,8 % mit SOX
  • R0-Resektion und 3-Jahres-PFS unter DOS numerisch höher
  • Verträglichkeit von DOS und SOX ähnlich

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Gastric Cancer, online erschienen am 08.03.2024. Verfasst von Zhichao Jiang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sci…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It remains unclear whether addition of docetaxel to the combination of a platinum and fluoropyrimidine could provide more clinical benefits than doublet chemotherapies in the perioperative treatment for locally advanced gastric/gastro-esophageal junction (LAG/GEJ) cancer in Asia. In this randomized, phase 2 study, we assessed the efficacy and safety of perioperative docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) in LAG/GEJ adenocarcinoma patients.

Methods

Patients with cT3–4 N any M0 G/GEJ adenocarcinoma were randomized (1:1) to receive 4 cycles of preoperative DOS or SOX followed by D2 gastrectomy and another 4 cycles of postoperative chemotherapy. The primary endpoint was major pathological response (MPR).

Results

From Aug, 2015 to Dec, 2019,154 patients were enrolled and 147 patients included in final analysis, with a median age of 60 (26–73) years. DOS resulted in significantly higher MPR (25.4 vs. 11.8%, P = 0.04). R0 resection rate, the 3-year PFS and 3-year OS rates were 78.9 vs. 61.8% ( P = 0.02), 52.3 vs. 35% (HR 0.667, 95% CI: 0.432–1.029, Log rank P = 0.07) and 57.5 vs. 49.2% (HR 0.685, 95% CI: 0.429–1.095, Log rank P = 0.11) in the DOS and SOX groups, respectively. Patients who acquired MPR experienced significantly better survival. DOS had similar tolerance to SOX.

Conclusions

Perioperative DOS improved MPR significantly and tended to produce longer PFS compared to SOX in LAG/GEJ cancer in Asia, and might be considered as a preferred option for perioperative chemotherapy and worth further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAdenocarcinomaEsophageal NeoplasmsHumansMiddle AgedAgedDocetaxelOxaliplatinAntineoplastic Combined Chemotherapy ProtocolsEsophagogastric Junction

Stichwörter der Autor:innen

DOSGastric cancerPerioperative chemotherapySOX

Substanzen

DocetaxelOxaliplatin

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, No. 17, Panjiayuannanli Stree…
  • Department of Pancreatic and Gastric Surgery, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021,…
  • Department of Pathology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Department of Imaging Diagnosis, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Department of Endoscopy, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Department of Thoracic Surgery, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

ORCID-Profile: Aiping Zhou

Zitieren

APA

Jiang, Z., Xie, Y., Zhang, W., Du, C., Zhong, Y., Zhu, Y., Jiang, L., Dou, L., Shao, K., Sun, Y., Xue, Q., Tian, Y., Gao, S., Zhao, D., & Zhou, A. (2024). Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial. Gastric Cancer, 27(3), 571-579. https://doi.org/10.1007/s10120-024-01471-z

Vancouver

Jiang Z, Xie Y, Zhang W, Du C, Zhong Y, Zhu Y, et al. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial. Gastric Cancer. 2024;27(3):571-579. doi:10.1007/s10120-024-01471-z

BibTeX
@article{Jiang2024,
  author = {Jiang, Zhichao and Xie, Yibin and Zhang, Wen and Du, Chunxia and Zhong, Yuxin and Zhu, Yuelu and Jiang, Liming and Dou, Lizhou and Shao, Kang and Sun, Yongkun and Xue, Qi and Tian, Yantao and Gao, Shugeng and Zhao, Dongbing and Zhou, Aiping},
  title = {Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial},
  journal = {Gastric Cancer},
  year = {2024},
  volume = {27},
  number = {3},
  pages = {571--579},
  doi = {10.1007/s10120-024-01471-z}
}
Kostenlos starten →